1
Stéphane De Lombaert
Rajagopal Bakthavatchalam, Charles A Blum, Harry Brielmann, Timothy M Caldwell, Stéphane De Lombaert, Kevin J Hodgetts, Xiaozhang Zheng, Taeyoung Yoon: Substituted quinazolin-4-ylamine analogues. Neurogen Corporation, Edwards Angell Palmer & Dodge, Peter F Corless, Mark D Russett, December 4, 2007: US07304059 (3 worldwide citation)

Substituted quinazolin-4-ylamine analogues are provided. Such compounds are ligands that may be used to modulate specific receptor activity in vivo or in vitro, and are particularly useful in the treatment of conditions associated with pathological receptor activation in humans, domesticated compani ...


2
Stéphane De Lombaert
Rajagopal Bakthavatchalam, Charles A Blum, Harry Brielmann, Stéphane De Lombaert, Xiaozhang Zheng: Substituted (7-pyridyl-4-phenylamino-quinazolin-2-yl)-methanol analogues. Neurogen Corporation, Edwards Angell Palmer & Dodge, Peter F Corless, Mark D Russett, February 12, 2008: US07329664 (2 worldwide citation)

Substituted (7-pyridyl-4-phenylamino-quinazolin-2-yl)-methanol analogues are provided. Such compounds are ligands that may be used to modulate specific receptor activity in vivo or in vitro, and are particularly useful in the treatment of conditions associated with pathological receptor activation i ...


3
Kevin Rodzinak
Donna J Armstrong, Essa H Hu, Michael J Kelly III, Mark E Layton, Yiwei Li, Jun Liang, Kevin J Rodzinak, Michael A Rossi, Philip E Sanderson, Jiabing Wang: Inhibitors of akt activtiy. Merck, September 2, 2010: US20100222321-A1

The instant invention provides for substituted naphthyridine compounds that inhibit Akt activity. In particular, the compounds disclosed selectively inhibit one or two of the Akt isoforms. The invention also provides for compositions comprising such inhibitory compounds and methods of inhibiting Akt ...


4

5
Prabhu Mohapatra
Laxminarayan Bhat, Prabhu Prasad Mohapatra, Sureshbabu Dadiboyena, Kouacou Adiey: Compositions, synthesis, and methods of utilizing quinazolinedione derivatives. Reviva Pharmaceuticals, Perkins Coie, Viola T Kung, November 5, 2013: US08575185

The present invention provides quinazolinedione derivatives of Formulae Ia and Ib, which can be advantageously used for treating schizophrenia and related psychoses such as acute manic, bipolar disorder, autistic disorder, depression and dementia.


6
Barker Andrew John: Quinazoline derivatives.. Zeneca, October 20, 1993: EP0566226-A1 (278 worldwide citation)

The invention concerns quinazoline derivatives of the formula I wherein m is 1, 2 or 3 and each R includes hydroxy, amino, carboxy, carbamoyl, ureido, (1-4C)alkoxycarbonyl, N-(1-4C)alkylcarbamoyl, N,N-di-[(1-4C)alkyl]carbamoyl, hydroxyamino, (1-4C)alkoxyamino, (2-4C)alkanoyloxyamino, trifluoromethox ...


7
Barker Andrew John, Davies David Huw: Therapeutic preparations containing quinazoline derivatives.. Ici, December 30, 1992: EP0520722-A1 (185 worldwide citation)

The invention concerns a pharamceutical composition which comprises known or novel quinazoline derivatives of the formula I wherein, for example, R is hydrogen, trifluoromethyl or nitro, n is 1 and R is halogeno, trifluoromethyl, nitro, cyano, (1-4C)alkyl, (1-4C)alkoxy, N-(1-4C)alkylamino, N,N-di-(( ...


8
Barker Andrew John, Brown Dearg Sutherland: Quinazoline derivatives.. Zeneca, June 22, 1994: EP0602851-A1 (147 worldwide citation)

The invention concerns quinazoline derivatives of the formula I wherein m is 1, 2 or 3 and each R includes hydroxy, amino, ureido, hydroxyamino, trifluoromethoxy, (1-4C)alkyl, (1-4C)alkoxy and (1-3C)alkylenedioxy; and and Q is a 9- or 10-membered bicyclic heterocyclic moiety containing one or two ni ...


9
Hayakawa Masahiko, Kaizawa Hiroyuki, Moritomo Hiroyuki, Kawaguchi Ken Ichi, Koizumi Tomonobu, Yamano Mayumi, Matsuda Koyo, Okada Minoru, Ohta Mitsuaki: Condensed heteroaryl derivatives. Yamanouchi Pharma, Ludwig Inst Cancer Res, Imp Cancer Res Tech, January 22, 2003: EP1277738-A1 (120 worldwide citation)

The present invention provides a pharmaceutical composition which is useful as a phosphatidylinositol 3 kinase (PI3K) inhibitor and an antitumor agent, and it provides a novel bicyclic or tricyclic fused heteroaryl derivative or a salt thereof which possesses an excellent PI3K inhibiting activity an ...


10
Hayflick Joel S, Pefaur Noah, Puri Kamal D, Tino William, Kawakami Toshi, Kawakami Yuko: Methods for treating mast cell disorders. Icos Corporation, La Jolla Institute For Allergy And Immunology, Hayflick Joel S, Pefaur Noah, Puri Kamal D, Tino William, Kawakami Toshi, Kawakami Yuko, NEVILLE Katherine L, December 22, 2005: WO/2005/120511 (116 worldwide citation)

The present invention provides methods of inhibiting mast cell activity by administering a selective inhibitor of phosphoinositide 3-kinase delta (P13K&dgr;). The invention also provides methods for treating or preventing a condition associated with undesirable mast cell activity in an individual co ...